financetom
Forex World Market Business Cryptocurrency Commodities MAP
financetom
Business
financetom
/
Business
/
AstraZeneca Says Potential Lung Cancer Treatment Improved Overall Survival Compared With Chemotherapy
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
AstraZeneca Says Potential Lung Cancer Treatment Improved Overall Survival Compared With Chemotherapy
May 28, 2024 2:23 AM

05:07 AM EDT, 05/28/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Monday its datopotamab deruxtecan therapy showed "clinically meaningful" improvement in overall survival rates over chemotherapy in nonsquamous non-small cell lung cancer patients during a phase 3 trial.

The 600-patient trial of the therapy previously met the primary endpoint of improvement in progression-free survival compared with docetaxel chemotherapy, although "survival results did not reach statistical significance in the overall trial population," the company said.

Datopotamab deruxtecan is being jointly developed by AstraZeneca ( AZN ) and Daiichi Sankyo.

The latest results "support applications" under review by regulators including in the US and European Union, AstraZeneca ( AZN ) said.

Price: 78.25, Change: -0.29, Percent Change: -0.38

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Mitsubishi UFJ Financial Announces New Business Plan to Increase Profitability
Mitsubishi UFJ Financial Announces New Business Plan to Increase Profitability
Apr 1, 2024
11:56 AM EDT, 04/01/2024 (MT Newswires) -- Mitsubishi UFJ Financial Group ( MUFG ) said Monday it has drawn up a new medium-term business plan that includes the financial target to increase return on equity to about 9% in fiscal year 2026. The new plan, which covers three years starting fiscal year 2024, focuses on growth strategies, social and environmental...
 Autolus Therapeutics Appoints Mike Bonney as Chair
Autolus Therapeutics Appoints Mike Bonney as Chair
Apr 1, 2024
11:53 AM EDT, 04/01/2024 (MT Newswires) -- Autolus Therapeutics ( AUTL ) said Monday it has appointed Mike Bonney as chair, effective immediately. Bonney succeeded John Johnson, who stepped down from the role, the company said. He previously served as chief executive of Cubist Pharmaceuticals. Shares of the company fell more than 10% in recent trading. Price: 5.73, Change: -0.65,...
 Solstice Gold Appoints Laycock as Chief Financial Officer
Solstice Gold Appoints Laycock as Chief Financial Officer
Apr 1, 2024
11:54 AM EDT, 04/01/2024 (MT Newswires) -- Solstice Gold ( SGCPF ) on Monday said it appointed Mark Laycock as its chief financial officer. The company said Laycock has over 15 years of accounting and finance experience in both private and public companies listed on Canadian and U.S. stock exchanges. Over the past five years Laycock has provided senior accountant...
 Update: dynaCERT Edges Down as it Suspends Purchase Order Of HydraGEN Technology Units In Guyana
Update: dynaCERT Edges Down as it Suspends Purchase Order Of HydraGEN Technology Units In Guyana
Apr 1, 2024
11:58 AM EDT, 04/01/2024 (MT Newswires) -- dynaCERT Inc. (DYA.TO), a developer of carbon emission reduction technology, said over the weekend that it indefinitely suspended a purchase order of its HydraGEN Technology units in Guyana, citing delivery issues and related litigation. The company previously said it delayed deliveries to the recipient pending further notice that certain outstanding issues had been...
About
Terms and Conditions Privacy policy Cookie Settings Contact Us
Services
Login register
financetom Market Personal Finance Business Economy Cryptocurrency MAP
Links
zpostcode Recruit weather mreligion Yellowpages sport constellation shopping name game directory literature Word tour furnish Lottery tftnews lyrics News digital car dir Edu Finance
Copyright 2023-2026 - www.financetom.com All Rights Reserved